ArticleAmerican journal of cancer research2026
Study on the effects of statin use in immunotherapy for elderly cancer patients on immune-related adverse reactions and quality of life.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effects of statins on immune-related adverse reactions, quality of life, and clinical outcomes in older adults receiving cancer immunotherapy.
methodsWe retrospectively enrolled 150 elderly cancer patients admitted to Beijing Shunyi Hospital between August 2023 and March 2025, who were categorized into a study group (
resultsNo significant differences were observed in general characteristics, clinical efficacy, or most laboratory indicators between the two groups (all
conclusionIn elderly cancer patients receiving immunotherapy, concomitant statin use did not increase adverse reactions, may improve quality of life, and did not compromise clinical efficacy. The observed PFS benefit was modest. Statins should be considered as an adjunctive therapy, with decisions individualized based on lipid profile and cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.